Dova Pharmaceuticals, Inc. has entered into an agreement through its wholly owned subsidiary, AkaRx, Inc., granting Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd., a wholly owned subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd., the exclusive development and distribution rights of avatrombopag in mainland China and Hong Kong.

As per the agreement, Fosun Pharma Industrial has the right to exclusively develop and commercialize and to assist AkaRx with the registration of avatrombopag for chronic liver disease (CLD) patients with thrombocytopenia in mainland China and Hong Kong.

Further, Fosun Pharma Industrial will also support the development of avatrombopag for expanded indications in mainland China and Hong Kong. 

US based Dova Pharmaceuticals is focused on acquiring, developing, and commercializing drug candidates for rare diseases where there is a high unmet need.